GT Medical Technologies, Inc
$1.8M 808 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Aegis Spine, Inc.
Aegis Spine, Inc. reported $1,763,749.82 across General Payments, Research, and Ownership to 38 physicians and teaching hospitals across 45 transactions.
- $1.8M Top quartile payer
- All-tracks total
- 45 Below-median volume
- Transactions
- 38 Below-median reach
- Recipients
- +$179.3K
- General Payments vs PY2023
Aegis Spine, Inc. reported $1,763,749.82 across all CMS Open Payments tracks (General + Research + Ownership) to 38 physicians and teaching hospitals in Program Year 2024 - ranking #480 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $334,321.82, averaging $46.4K per recipient.
How Aegis Spine, Inc.'s $1.8M all-tracks total breaks down
Aegis Spine, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
17/100
Total payments
F
26/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer aegis-spine-inc Aegis Spine, Inc.
$1.8M · #480/1,925 · 0.0% industry · PY2024
- TOT $1.8M
- RANK #480
- SHARE 0.0%
- TXN 45
- RCP 38
- CAT 2
- GEN $334.3K
- ΔGEN +$179.3K
- TOP1 43.1%
- PY 2024
Volume peers
Nearest volume peer: GT Medical Technologies, Inc ($1.8M)
Aegis Spine, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Aegis Spine, Inc.'s CMS-reported General Payments increased by $179.3K (+115.7%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: AEGIS SPINE, INC.PY2023: AEGIS SPINE, INC.PY2024: Aegis Spine, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $155,002.75
- PY2024
- $334,321.82
What the Data Shows for Aegis Spine, Inc.
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For Aegis Spine, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
"Consulting Fee" leads the 2-category general-payment breakdown below at $319.2K (95.5% of General Payments, 31 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Across 2 types of general payments, Aegis Spine, Inc.'s largest category was "Consulting Fee" at $319.2K - 95.5% of General Payments.
How Aegis Spine, Inc. divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $319.2K | 31 | 95.5% |
| Travel and Lodging | $15.1K | 7 | 4.5% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $320,732.33 (95.9%) of $334,321.82 in this company's General Payments records across 9 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Aegis Spine, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Jayant Jagannathan
$144,000.00 across 12 reported transactions
- 2
John Difiore
$142,200.00 across 11 reported transactions
- 3
Michael Oh
$19,332.33 across 2 reported transactions
- 4
Tuan Bui
$8,000.00 across 2 reported transactions
- 5
Terrence Crowder
$7,200.00 across 4 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Aegis Spine, Inc.'s spend rank (#480 of 1,925, top 25% by spend) and concentration rank (#476 of 1,838, top 26% most concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- SN Holdings, LLC : $104.9K total payments, HHI 3766
- LINA Medical USA Inc : $2.0K total payments, HHI 3750
- Visionary Optics LLC : $78.8K total payments, HHI 3743
- Captiva Spine Inc : $227.0K total payments, HHI 3740
- Rejoni Inc. : $331.1K total payments, HHI 3727
- Elekta Pty Ltd : $117.64 total payments, HHI 3726
- Aegis Spine, Inc. (this company) : $334.3K total payments, HHI 3714
- One Lambda, Inc. : $150.1K total payments, HHI 3711
- Nurami Medical Ltd : $627.48 total payments, HHI 3707
- Pristine Surgical LLC : $19.0K total payments, HHI 3684
- Circle Cardiovascular Imaging Inc. : $14.6K total payments, HHI 3678
- Merakris Therapeutics, Inc. : $10.4K total payments, HHI 3674
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Aegis Spine, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Aegis Spine, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Aegis Spine, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Amylyx Pharmaceuticals, Inc.
$1.8M 344 recipients
Compare payment profiles
Preceptis Medical, Inc.
$1.8M 109 recipients
Compare payment profiles
Medivation LLC.
$1.7M 3 recipients
Compare payment profiles
Radiometer America, Inc
$1.7M 84 recipients
Compare payment profiles
Dendreon Pharmaceuticals LLC
$1.8M 10,334 recipients
Compare payment profiles
Put this to use
Aegis Spine, Inc. ranks #480 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See where Aegis Spine, Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just Aegis Spine, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.